LYTACs induce selective degradation of extracellular proteins by recruiting them to cellular receptors that mediate delivery to the lysosome. Recent development of GalNAc-LYTACs and MoDE-As targeting the liver-specific ASGPR enables cell-type-restricted lysosomal protein degradation and reveals new LYTAC design principles.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
Cancer and Metastasis Reviews Open Access 14 October 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gerry, C. J. & Schreiber, S. L. Nat. Chem. Biol. 16, 369–378 (2020).
Pettersson, M. & Crews, C. M. Drug Discov. Today Technol. 31, 15–27 (2019).
Takahashi, D. et al. Mol. Cell 76, 797–810.e10 (2019).
Li, Z. et al. Nature 575, 203–209 (2019).
Banik, S. M. et al. Nature 584, 291–297 (2020).
Ahn, G. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-021-00770-1 (2021)
Caianiello, D. F. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-021-00851-1 (2021).
Zhou, Y., Teng, P., Montgomery, N. T., Li, X. & Tang, W. ACS Cent. Sci. 7, 499–506 (2021).
Uhlén, M. et al. Science 347, 1260419 (2015).
Attwood, M. M., Jonsson, J., Rask-Andersen, M. & Schiöth, H. B. Nat. Rev. Drug Discov. 19, 695–710 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.P. is an employee of Novartis.
Rights and permissions
About this article
Cite this article
Paulk, J. Lysosome-targeting chimeras evolve. Nat Chem Biol 17, 931–933 (2021). https://doi.org/10.1038/s41589-021-00835-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-021-00835-1
This article is cited by
-
Emerging roles of deubiquitinating enzymes in actin cytoskeleton and tumor metastasis
Cellular Oncology (2024)
-
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
Cancer and Metastasis Reviews (2022)